News from the FDA/CDC

FDA issues new NSAIDs warning for second half of pregnancy


 

The U.S. Food and Drug Administration released new warnings Oct. 15 that most nonsteroidal anti-inflammatory agents (NSAIDs) carry an elevated risk for kidney complications in unborn children when taken around weeks 20 or later in pregnancy.

Citing newly available research, the agency states the risk of low amniotic fluid (known as oligohydramnios) can occur, which in turn can cause rare but serious kidney problems in the offspring. Pregnancy complications also can result.

The FDA action expands on earlier warnings about agents in this drug class, which the FDA previously cautioned about taking after week 30 of pregnancy because of heart-related risks.

Manufacturers of both over-the-counter and prescription NSAIDs – including ibuprofen, naproxen, diclofenac, and celecoxib – will be required to update their labeling with the new warning.

Low-dose (81-mg) aspirin is excluded from this warning.

“Low-dose aspirin may be an important treatment for some women during pregnancy and should be taken under the direction of a healthcare professional,” the agency stated in a news release.

“It is important that women understand the benefits and risks of the medications they may take over the course of their pregnancy,” Patrizia Cavazzoni, MD, acting director of FDA’s Center for Drug Evaluation and Research, states in the release. “To this end, the agency is using its regulatory authority to inform women and their healthcare providers about the risks if NSAIDs are used after around 20 weeks of pregnancy and beyond.”

Oligohydramnios can arise quickly – in as little as 2 days – or weeks after starting regular NSAID use in this patient population. The condition usually resolves if a pregnant woman stops taking the NSAID, the agency notes.

If a health care provider believes NSAIDs are necessary between about 20 and 30 weeks of pregnancy, use should be limited to the lowest effective dose and shortest duration possible, the Drug Safety Communication notes.

As a reminder, health care professionals and patients should report side effects from NSAIDs to the FDA’s MedWatch program.

A version of this article originally appeared on Medscape.com.

Recommended Reading

Pandemic drives demand for self-managed abortions
MDedge ObGyn
Nearly half of brachial plexus injury cases occur without shoulder dystocia
MDedge ObGyn
Women with MS may have increased subclinical disease activity during pregnancy
MDedge ObGyn
Pregnancy studies on psoriasis, PsA medications pick up
MDedge ObGyn
FDA proposes withdrawing Makena’s approval
MDedge ObGyn
Please stop using the adjective “elective” to describe the important health services ObGyns provide
MDedge ObGyn
The professional advancement of drug and device innovation
MDedge ObGyn
Work-life balance: How 5 surgeons manage life in and out of the operating room
MDedge ObGyn
Enhanced recovery program improves outcomes after cesarean delivery
MDedge ObGyn
Social factors predicted peripartum depressive symptoms in Black women with HIV
MDedge ObGyn